Clinical observations with Paxirasol nasal spray.
The effect of Paxirasol nasal spray has been examined in 25 patients by the open method. The goal of the study was to assess and evaluate the clinical effectivity of the product and to observe the eventual side-effects. Among the examined patients 14 were acute and 11 chronic disease cases. In 20 of the 25 patients treated with Paxirasol nasal spray the pathological alteration of the nasal mucosa was controlled, mild alteration persisted in 4 patients, and moderately severe condition in 1 patient. The product significantly improved the viscosity of nasal discharge in all of them. The cessation or moderation of difficult nose blowing improved the general condition of the patients and accelerated recovery. Occasionally manifesting olfactory disorders ceased as well. The treatment needed not be discontinued because of the development of side-effects. Considering the healing tendency difference could be observed between the acute and chronic cases, especially in rhinitis sicca patients who were treated with Paxirasol nasal spray. In 23 of the 25 patients notable improvement of both the subjective and objective symptoms was observed. Paxirasol nasal spray is of value in very frequently occurring diseases of the nasal mucosa accompanied by dehydration. In the majority of acute disease patients the use of the product as monotherapy may result in complete cessation of symptoms.
Szabadka
H
H
Department of Otorhinolaryngology, Bajcsy-Zsilinszky Hospital-Outpatient Clinic, Budapest.
D000281:Administration, Intranasal; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001964:Bromhexine / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007440:Intubation / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009297:Nasal Mucosa / Q000187:drug effects / Q000293:injuries; D010612:Pharyngitis / Q000188:drug therapy*; D012220:Rhinitis / Q000188:drug therapy*; D013997:Time Factors
D001964:Bromhexine